Skip to main content


Freshfields advises on listing of Hangzhou Tigermed Consulting Company Limited in Hong Kong

Freshfields Bruckhaus Deringer (‘Freshfields’) has advised the joint sponsors and underwriters in the global offering and listing of the H shares of Hangzhou Tigermed Consulting Company Limited (‘Hangzhou Tigermed’) on the Hong Kong Stock Exchange. Trading in the shares commenced today (7 August 2020). The global offering raised proceeds of US$1.38 billion and is the largest healthcare IPO in Hong Kong in 2020 to date.

Hangzhou Tigermed is a leading China-based provider of comprehensive biopharmaceutical R&D services, with an expanding global presence. According to industry research, it was the largest clinical research organisation in China in terms of revenue in 2019.  Its A shares were listed on the Shenzhen Stock Exchange in 2012. Among other purposes, Hangzhou Tigermed intends to use the proceeds of the global offering to expand and enhance its service offerings and capabilities in overseas markets, fund potential acquisitions of attractive overseas assets and enhance its overall technology platform and data infrastructure.

The Freshfields team also advised Frontage Holdings Corporation, a subsidiary of Hangzhou Tigermed, on its listing on the Hong Kong Stock Exchange in 2019.
The Freshfields team advising on the transaction was led by partners Grace Huang and Arun Balasubramanian.


Notes for Editors:

About Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer LLP is a global law firm with a long track record of successfully advising the world's leading national and multinational corporations and financial institutions on groundbreaking and business-critical challenges. Our team of more than 2,800 lawyers and other legal professionals delivers global results from our 27 offices worldwide. Our commitment, local and multinational expertise and business know-how means our clients can rely on us when it matters most.